- Home
- ACON vs KTTA Comparison
ACON vs KTTA Comparison
Compare ACON & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- KTTA
- Stock Information
- Founded
- ACON 2008
- KTTA 2020
- Country
- ACON United States
- KTTA United States
- Employees
- ACON N/A
- KTTA N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- KTTA Health Care
- Exchange
- ACON Nasdaq
- KTTA Nasdaq
- Market Cap
- ACON 4.5M
- KTTA 5.1M
- IPO Year
- ACON 2022
- KTTA 2021
- Fundamental
- Price
- ACON $7.47
- KTTA $0.73
- Analyst Decision
- ACON Buy
- KTTA
- Analyst Count
- ACON 2
- KTTA 0
- Target Price
- ACON $481.00
- KTTA N/A
- AVG Volume (30 Days)
- ACON 13.2K
- KTTA 113.1K
- Earning Date
- ACON 08-13-2025
- KTTA 08-12-2025
- Dividend Yield
- ACON N/A
- KTTA N/A
- EPS Growth
- ACON N/A
- KTTA N/A
- EPS
- ACON N/A
- KTTA N/A
- Revenue
- ACON $54,601.00
- KTTA N/A
- Revenue This Year
- ACON $145.39
- KTTA N/A
- Revenue Next Year
- ACON $145.45
- KTTA N/A
- P/E Ratio
- ACON N/A
- KTTA N/A
- Revenue Growth
- ACON N/A
- KTTA N/A
- 52 Week Low
- ACON $6.20
- KTTA $0.65
- 52 Week High
- ACON $3,499.51
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- ACON 49.34
- KTTA 44.60
- Support Level
- ACON $7.12
- KTTA $0.68
- Resistance Level
- ACON $7.60
- KTTA $0.75
- Average True Range (ATR)
- ACON 0.35
- KTTA 0.03
- MACD
- ACON 0.04
- KTTA 0.01
- Stochastic Oscillator
- ACON 55.72
- KTTA 78.35
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).